Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Feb 12, 2024 12:02pm
161 Views
Post# 35875658

RE:Unleasing Viruses aimed at Killing Cancer.

RE:Unleasing Viruses aimed at Killing Cancer.

There are mutiple good study results with the last 12 months.
Yes, there have been ample failures. That is part of the biotech world.
Even the best & biggest pharma companies have mutiple failures.
Years ago I was invited to be part of a phase 2 trial, 
interviews, massive forms to fill out. More interviews. 
For mostly time availability reasons I dropped out before the first stage of trial.
That biotech company was bought out. The trial did continue.
Failed miserably. The results were positive, yet the " control" parameters & " reporting of participants was deemed to be " too unpredictable" , there by nullifying any results.
In simple terms the trial parameters needed to be better understood & controlled.
My point?
All FDA approval trials are extremely complicated.
Back to Onc, as was pointed out. Great results  with the CAR-T, in a few examples. Total elimination of the tumour.
That was over a year ago. We were told, " mutiple NDA agreements & additional trials" ...hoping to lead to a form of licensing agreement. So far nothing.
The most recent & much more relevant is the Gobblet trial with Roche.
A 4 arm study. With 3 of the 4 showing positions results.
The pancreatic cancer results came out, showing 3x improvement over exiting standard of care.
That lesd to a very quick fast track designation from FDA & acceptance from PanCan into their precision promise program.
At that period of time. ( late 2023), things looked great.
Then PanCan announced cancellation of ALL programs within the precicion promise program.
aessentially they did not get funding they were expecting.
That kick in the pants ( Dec 2023) , left ONC with a nice plan, but no funding.
Obviously the SP tanked.
So here we are. Two phase 3 , fast track FDA ready to go, yet no trial details or parameters.
Onc announced details will follow.
The good news, they still have Roche Tecentriq as the co- therapy to be moved forward into the phase 3 , for the pancreatic cancer.
What we don't know is how? 

When will it start, the parameters, who will assist with funding?
mutiple options. 

parnership with Roche?
conplete buyout?
massive public offering under a restructuring?
Onc can not fund a phase 3 trial under present day financial model.
so......something has to change & soon.
im expecting the best.
The silence is deafening. Indicates either. Nothing at all to report,
or 
A NDA publication black out.
One of which is very bad , the other very good.
regardless the SP moves in anticipation of the big unknown.
Today, up slightly from the recent very low numbers last week.
Being an optimistic person & belive in the science, I put  my $$ where my mouth is & bought some more. , moan complain...or average down.
It is at this juncture a very serious cross roads. They MUST have additional influx of cash, very soon.
Good news going forward & the SP climbs rapidly. Dollars PS not pennies.
Bad news? No idea. Like I said, even a fire sale. The SP is worth mor3 than its present trading, for its cumulative tax loss.
So, have a good day all.
BTW , who kidnapped Notable 


 

<< Previous
Bullboard Posts
Next >>